HUTCHMED Confident In Sovleplenib For Hemolytic Anemia After New Results

First-In-Class Syk Inhibitor For Indication

 
• By Xu Hu
  
A sign of hemolytic anemia
HUTCHMED plans to file the new drug application for sovleplenib in warm autoimmune hemolytic anemia in H1 of 2026 in China. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from China